Delays in breast cancer diagnosis after a state policy limiting Medicaid enrollment-Reference-Cited by-同舟云学术

Delays in breast cancer diagnosis after a state policy limiting Medicaid enrollment

Published:2017-06-26 Issue:17 Volume:123 Page:3219-3221
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Subramanian Sujha¹^ORCID,Keating Nancy L.²³

Affiliation:

1. Public Health Research Division; RTI International; Waltham Massachusetts

2. Department of Health Care Policy; Harvard Medical School; Boston Massachusetts

3. Division of General Internal Medicine; Brigham and Women's Hospital; Boston Massachusetts

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30769/fullpdf

Reference13 articles.

1. Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment;Tarazi;Cancer.,2017

2. TennCare II Section 1115 demonstration: fact sheet https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Waivers/1115/downloads/tn/tn-tenncare-ii-fs.pdf 2017

3. TennCare disenrollment and avoidable hospital visits in Davidson County, Tennessee;Emerson;J Health Care Poor Underserved.,2012

4. Access to care and chronic disease outcomes among Medicaid-insured persons versus the uninsured;Christopher;Am J Public Health.,2016

5. Health insurance status change and emergency department use among US adults;Ginde;Arch Intern Med.,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation between rs13347 polymorphism of CD44 gene and the risk of occurring breast cancer;Medicine;2021-06-04

2. Clinical value of color Doppler ultrasound combined with serum CA153, CEA and TSGF detection in the diagnosis of breast cancer;Experimental and Therapeutic Medicine;2020-06-10

3. Relationship Study of The Verified Human Epidermal Growth Factor Receptor 2 Amplification with Other Tumor Markers and Clinicohistopathological Characteristics in Patients with Invasive Breast Cancer, Using Chromogenic In Situ Hybridization;CELL J;2019